Systems Biology: A Very Short Introduction

In the postgenomic era, the large-scale data, such as genome sequences, mRNA sequences, and protein sequences, increase rapidly. It is desired to develop the computational approaches that can derive and analyze useful information from them to promote the development of biomedicine and drug design. Meanwhile, in order to understand how proteinprotein interactions and other complex interactions in a living system get integrated in complex nonlinear networks and regulate cell function, a new discipline, called "Systems Biology", is created.

Fine-Grained Parallel and Distributed Spatial Stochastic Simulation of Biological Reactions

Praise for Computational Systems BiologyApproaches in Cancer Research: "Complex concepts are written clearly and with informative illustrations and useful links. The book is enjoyable to read yet provides sufficient depth to serve as a valuable resource for both students and faculty." — Trey Ideker, Professor of Medicine, UC Xan Diego, School of Medicine "This volume is attractive because it addresses important and timely topics for research and teaching on computational methods in cancer research. It covers a broad variety of approaches, exposes recent innovations in computational methods, and provides acces to source code and to dedicated interactive web sites." — Yves Moreau, Department of Electrical Engineering, SysBioSys Centre for Computational Systems Biology, University of Leuven With the availability of massive amounts of data in biology, the need for advanced computational tools and techniques is becoming increasingly important and key in understanding biology in disease and healthy states. This book focuses on computational systems biology approaches, with a particular lens on tackling one of the most challenging diseases - cancer. The book provides an important reference and teaching material in the field of computational biology in general and cancer systems biology in particular. The book presents a list of modern approaches in systems biology with application to cancer research and beyond. It is structured in a didactic form such that the idea of each approach can easily be grasped from the short text and self-explanatory figures. The coverage of topics is diverse: from pathway resources, through methods for data analysis and single data analysis to drug response predictors, classifiers and image analysis using machine learning and artificial intelligence approaches. Features Up to date using a wide range of approaches Applicationexample in each chapter Online resources with useful applications'

Preface. Abbreviations and Glossary. Part One. History. 1. Introduction. 2. The Early Period to 1850. 2.1 Introduction. 2.2 Experimental Scientific Findings. 2.3 Application. 2.4 Theoretical Approaches. References. 3. The Period from 1850 to 1890. 3.1 Introduction. 3.2 Experimental Findings. 3.3 Practical Application, Technical Progress and Institutional Development. 3.4 Theoretical Approaches. References. 4. The Period from 1890 to 1950. 4.1 Introduction. 4.2 Research Advances in the Basics of Biotechnology: Experimental Findings. 4.3 Technological Development, Progress and Application. 4.4 Theoretical Approaches. References. 5. Outlook, from 1950 Onwards: Biotechnology Science or What? 5.1 Introduction. 5.2 Traditional Biotechnology and the Decehma Report. 5.3 The Changing Focus in BT in the USA in the Early 1980s. 5.4 Conclusions. References. Part Two The New Paradigm Based on Molecular Biology and Genetics. 6. Broadening of Biotechnology through Understanding Life, Genetics and Evolution. References. 7. The Beginning of the New Biotechnology. 7.1 Introduction. 7.2 The Beginnings of Evolution Theory and Genetics. 7.3 The Origin of Recombinant DNA Technology. 7.4 Oligonucleotide Synthesis Leads to Protein Engineering. 7.5 Synthetic DNA, Reverse Transciptase: Isolating Genes. 7.6 Biodiversity and Gene Mining. 7.7 Creating New Diversity by Design or Empirically. 7.8 Genetic Fingerprinting . 7.9 Inheritable Predisposition to Disease. References. 8. Ethical Aspects Related to Genome Research, and Reproductive Medicine. 8.1 Negative Public Reaction to Gene Technology. 8.2 Ethical Aspects: Animal Cloning and Fertility Research. References. 9. Elucidating Protein Structure: The Beginnings of Rational Protein Design. 9.1 Cambridge England, the Cradle of Structural Analysis of Macromolecules. 9.2 Redesigning the Protein Core. 9.3 Redesigning the Protein by Altering Primary Sequence. 9.4 Post Translational Modifications. 9.5 Total Chemical Synthesis. 9.6 Validation of Drug Design Based on the known Structure of the Target. 9.7 General Considerations in Drug Development. References. 10. The Development of Antibodies as Pharmaceutical Products. 10.1 An Introduction to the Immune System. 10.2 The Beginnings of Applied Immunology. 10.3 Monoclonal Antibodies. 10.4 Producing Antibodies via rDNA and Combinatorial Biology. 10.5 Affinity Enrichment on Surface of Immobilized Target Molecules. 10.6 Mice with Human Antibody Gene Repertoires. 10.7 Two Severe Setbacks during Clinical Testing. 10.8 A Survey of Therapeutic Antibodies. References. 11. Hereditary Disease and Human Genome Analysis. 11.1 Introduction. 11.2 Heredity Studies and Family Counselling . 11.3 Early Attempts to Analyse the Human Genome. 11.4 The Personalized Genome and Personal Medicine. 11.5 Analysing the Effect of the Environment on the Human Genome: Epigenetics. References. 12. Transgenic Animals and Plants. 12.1 Introduction. 12.2 Stem Cells and Gene Targeting. References. 13. Extrapolating to the Future. 13.1 Summary of the Status Quo. 13.2 Insect Control Through Sterile Males (SIT). 13.3 The Future of Gene Therapy. 13.4 Stem Cell Therapy. 13.5 Flash Sequencing DNA: A Human Genome Sequence in Minutes? 13.6 Systems Biology and Looking for Druggable Targets. 13.7 Synthetic Biology. References. 14. Biotechnology and Intellectual Property. 14.1 Introduction. 14.2 Patents Ensure Growth and Rapid Dissemination of Knowledge. 14.3 Owning a Patent does not simply Mean that it can be Implemented: Freedom to Operate (FTO). 14.4 Life-forms as Novel Subject Matter for Patents? 14.5 Technology State of the Art : Precedence/Directives, not Fixed by Law. 14.6 Who can make Decisions about Public Morality? 14.7 Biotechnology-oriented Directives Guide Patenting Decisions. References. Part Three. Application. 15. Bioprocess Engineering. 15.1 Introduction. 15.2 Aspects of Applied Microbiology. 15.3 Biocatalysis. 15.4 Biochemical Engineering. 15.5 Process Sustainability and Ecological Considerations. 15.6 Biosystems Engineering, including Omics Technologies. 15.7 Outlook and Perspectives. References. 16. Industrial Biotechnology. 16.1 Introduction. 16.2 General Aspects. 16.3 Commodities. 16.4 Chemicals. 16.5 Food Processing and Products. 16.6 Environmental Processes. 16.7 Summary, Trends and Perspectives. References. 17. Pharmaceutical Biotechnology. 17.1 Introduction. 17.2 Drug Targeting, Discovery Strategies and Development. 17.3 Pharmaceuticals Production. 17.4 Products, Pharmaceuticals Made by Biotechnology. 17.5 Medicinal Techniques, Diagnostics. 17.6 Business: Companies and Economic Aspects. References. 18. Plant Biotechnology. 18.1 Introduction. 18.2 Political, Ethical and Biosafety Aspects. 18.3 Research and Development. 18.4 Application of Modified Plants and Products. 18.5 Economic Aspects. 18.6 Summary and Outlook. References. Index.

Systems biology and systems medicine have played an important role in the last two decades in shaping our understanding of biological processes. While systems biology is synonymous with network maps and '-omics' approaches, it is not often associated with mechanical processes. Here, we make the case for considering the mechanical and geometrical aspects of biological membranes as a key step in pushing the frontiers of systems biology of cellular membranes forward. We begin by introducing the basic components of cellular membranes, and highlight their dynamical aspects. We then survey the functions of the plasma membrane and the endomembrane system in signaling, and discuss the role and origin of membrane curvature in these diverse cellular processes. We further give an overview of the experimental and modeling approaches to study membrane phenomena. We close with a perspective on the converging futures of systems biology and membrane biophysics, invoking the need to include physical variables such as location and geometry in the study of cellular membranes. WIREs Syst Biol Med 2017, 9:e1386. doi: 10.1002/wsbm.1386 For further resources related to this article, please visit the WIREs website.

Editorial overview: Systems biology for biotechnology

Carbonic anhydrase: chemistry, physiology, and inhibition.

Chapter 24 - Repurposing, effects, design, and discovery of drugs in systems biology

Spectacular developments in molecular and cellular biology have led to important discoveries in cancer research. Despite cancer is one of the major causes of morbidity and mortality globally, diabetes is one of the most leading sources of group of disorders. Artificial intelligence (AI) has been considered the fourth industrial revolution machine. The most major hurdles in drug discovery and development are the time and expenditures required to sustain the drug research pipeline. Large amounts of data can be explored and generated by AI, which can then be converted into useful knowledge. Because of this, the world's largest drug companies have already begun to use AI in their drug development research. In the present era, AI has a huge amount of potential for the rapid discovery and development of new anticancer drugs. Clinical studies, electronic medical records, high-resolution medical imaging, and genomic assessments are just a few of the tools that could aid drug development. Large data sets are available to researchers in the pharmaceutical and medical fields, which can be analyzed by advanced AI systems. This review looked at how computational biology and AI technologies may be utilized in cancer precision drug development by combining knowledge of cancer medicines, drug resistance, and structural biology. This review also highlighted a realistic assessment of the potential for AI in understanding and managing diabetes.

In his famous essay, Lazebnik [1] discussed whether a biologist can fix a broken radio and suggested that applying the ‘biologist approach’ to a broken radio will likely not lead to a successful end, while any engineer or even a trained repairman evidently could fix the radio. In biology, the study of molecules one by one is fine for gathering information on how molecules work, but deciphering biological mechanisms, or the function of biological systems, is a different story. One difference between an engineer and a biologist, according to Lazebnik, lies in the language: in biology, language is oftentimes vague and nonquantitative which limits the possibility of making predictions [1]. In systems biology, a quantitative and predictive language is adopted to describe biological knowledge in order to understand how molecules act together within the network of interactions that makes up a living system. Systems biology, in other words, is the holistic analysis of complex systems. Indeed, systems biology can be defined as the computational and mathematical modeling of complex biological systems, in contrast to the traditional, reductionist approach to biology. Common technology platforms that are deployed to obtain complex datasets are transcriptomics, proteomics, metabolomics and epigenomics. However, systems biology should not be seen merely as the generation of lists of genes, proteins or metabolites using such omics platforms; the objective is to exploit these data and to develop quantitative models that describe the biological system and its response to individual perturbations (see [2] for an excellent introduction to this subject). Furthermore, systems biology can be seen as an iterative interplay between discoveryand hypothesis-driven science: “global observations (discoveries) are matched against model predictions (hypotheses) in an iterative manner, leading to the formation of new models, new predictions, and new experiments to test them” [2]. Systems toxicology, in turn, has been described as “the integration of classical toxicology with quantitative analysis of large networks of molecular and functional changes occurring across multiple levels of biological organization”, and it has been suggested that its application could be part of a new and improved risk assessment [3]. This is nothing less than a paradigm shift in the way that toxicology is conducted. Importantly, systems toxicology – and systems biology in general – relies heavily on computational approaches to manage, analyze and interpret the data generated by large-scale experiments, and computer databases are thus an integral feature of this approach [2]. To this end, commonly accepted repositories and software environments are crucially important [4]. This does not mean that the introduction of systems toxicology approaches is breaking the rice bowl of the classically trained toxicologist. Instead, the ‘new’ toxicology is Systems biology in nanosafety research

Integrative physiology and systems biology: reductionism, emergence and causality

Chapter 7 - Systems biology, drug development, and clinical outcomes

Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development

Artificial intelligence (AI) is a subfield of computer science focused on developing systems that can execute tasks traditionally associated with human intelligence. AI systems work through algorithms based on rules or instructions that enable the machine to make decisions. With the advancement of science, more sophisticated AI techniques, such as machine learning and deep learning, have been developed, allowing machines to learn from large amounts of data and improve their performance over time. The pharmaceutical industry has greatly benefited from the development of this technology. AI has revolutionized drug discovery and development by enabling rapid and effective analysis of vast volumes of biological and chemical data during the identification of new therapeutic compounds. The algorithms developed can predict the efficacy, toxicity, and possible adverse effects of new drugs, optimize the steps involved in clinical trials, reduce associated time and costs, and facilitate the implementation of innovative drugs in the market, making it easier to develop precise therapies tailored to the individual genetic profile of patients. Despite significant advancements, there are still gaps in the application of AI, particularly due to the lack of comprehensive regulation. The constant evolution of this technology requires ongoing and in-depth legislative oversight to ensure its use remains safe, ethical, and free from bias. This review explores the role of AI in drug development, assessing its potential to enhance formulation, accelerate discovery, and repurpose existing medications. It highlights AI’s impact across all stages, from initial research to clinical trials, emphasizing its ability to optimize processes, drive innovation, and improve therapeutic outcomes.

Taking a byte out of big data